ScreenerHero

PTP Pentixapharm Holding AG

XETRA · DE · Healthcare · Biotechnology · pentixapharm.com
1.825EUR-1.35%Mkt Cap: 991848 $P/E: —

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap991.85K USD
Enterprise Value45.26M USD
Revenue (TTM)263.04K USD
Gross Profit-7.29M USD
Net Income (TTM)-17.95M USD
Revenue/Share0.01 EUR
Last Price1.825 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees38
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A40AEG0
Valuation
P/E (Trailing)—
P/E (Forward)-2.77
PEG—
EV/EBITDA-2.37
EV/Revenue172.05
P/S3.77
P/B1.59
EPS (TTM)-0.58
EPS (Forward)-0.66
52W Range
1.30022% of range3.700
52W High3.700 EUR
52W Low1.300 EUR
Profitability
Gross Margin-7207.53%
Oper. Margin-23880.00%
EBITDA Margin0.00%
Profit Margin-17753.76%
ROE-47.08%
ROA-39.44%
Growth
Revenue Growth-91.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.54M USD
CapEx (TTM)679.35K USD
FCF Margin-4078.62%
FCF Yield-1081.67%
Net Debt-3.91M USD
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity—
Current Ratio1.55
Quick Ratio1.26
Book Value/Sh1.15 EUR
Cash/Share0.14 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.265 EUR
Upside (mean)+407.7%
Target Range7.200 EUR – 11.33 EUR
7.200+407.7% to mean11.33
# Analysts2
Ownership
Shares Out.500.00K
Float18.09M
Insiders30.99%
Institutions6.06%
Technical
SMA 501.882 (-3.0%)
SMA 2002.015 (-9.4%)
Beta—
S&P 52W Chg14.58%
Avg Vol (30d)13.98K
Avg Vol (10d)10.97K
Technical Indicators
RSI (14)41.5
MACD-0.0138
MACD Signal-0.0116
MACD Hist.-0.0022
BB Upper1.921 EUR
BB Middle1.868 EUR
BB Lower1.815 EUR
BB Width5.65%
ATR (14)0.0631 EUR
Vol Ratio (20d)0.85x